Fetuses with a specific, rare chromosomal aberration have a 20% risk of developmental or other brain disorder, new research shows. The work could lead to personalised diagnostics and counselling for pregnant women.
New research shines a spotlight on the placenta’s critical role in the nature versus nurture debate and how it confers risk for schizophrenia and likely other neurodevelopmental disorders including ADHD, autism, and Tourette syndrome.
A group of clinical neurologists, molecular biologists and computer scientists have worked together to solve the mystery of why motor neurons die in patients with motor neuron disease.
J. Craig Venter shared on Twitter last week that he is retiring from Human Longevity, and returning to the J. Craig Venter Institute (JCVI) to continue his work.
The structure of DNA is widely accepted to exist as a double helix, but different DNA structures also exist. New research points to a range of triggers that can manipulate its shape.
Free download: This guide will discuss the gene editing tools currently available and how they can be used to manipulate genomic sequences, as well as the real world applications that put these tools to use.
This week’s talking points were how we’re all mosaics, the ‘Jolie Effect’ on breast cancer and that China is taking the lead in genetic testing.
It’s been a recurring refrain: Africa still lags woefully behind the rest of the world in generating new scientific knowledge. But there are several projects that offer hope amid all the bad news.
We now have the capacity to quickly and cheaply sequence an individual’s genome and scour it for disease-causing genes. But how much, and what type, of information does a parent-to-be want to know?
Genetics is influencing more and more of our decisions, but we can’t make the right choices if we don’t understand it.
A new technique reveals the earliest stages of human development without the need for human embryos.
The previous head of R&D and chief scientific officer at Gilead Sciences, Norbert Bischofberger has surfaced as the new CEO of startup Kronos Bio.
The FDA is coming down hard on pharma following generic drug stalling tactics. This follows the recent publication from the agency of an online list of pharma companies that together have racked up 150 complaints from generics makers seeking samples.
Merck & Co. already controls a big part of the first-line non-small cell lung cancer market, and it’s likely that it’s just secured most of the rest of it.
Experts are urging drugmakers to stick with developing an effective Ebola vaccine, because the world needs more than one.
